Infectologia

Merck autoriza que outros países produzam novo antiviral contra COVID-19.

28 Out, 2021 | 16:17h

Merck to allow other nations to produce new COVID-19 antiviral – CIDRAP

Ver também:

Merck will allow drugmakers in other countries to make its COVID-19 pill – NPR

Game-Changing COVID-19 Oral Treatment Set To Become Widely Accessible in Low- and Middle-Income Countries Upon Regulatory Approval – Health Policy Watch

Conteúdos relacionados:

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

---

Dois estudos observacionais levantam dúvidas sobre os efeitos do fechamento de escolas na redução da transmissão da Covid-19.

28 Out, 2021 | 16:15h

Estudo 1: No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020 – Nature Medicine

Estudo 2: The impact of school opening model on SARS-CoV-2 community incidence and mortality – Nature Medicine

 

Comentários no Twitter

Results from a study in the US published in @NatureMedicine indicate that schools can reopen for in-person learning without substantially increasing community case rates of SARS-CoV-2. However, the impacts are variable and more study is needed. https://t.co/NFt1vNNb76 pic.twitter.com/fNgsJn6WLg

— Nature Portfolio (@NaturePortfolio) October 27, 2021

(fio – clique para saber mais)

2 new @NatureMedicine papers
First from half of US public school data
"Schools can open for in-person learning during the pandemic with minimal contribution to sustained community incidence of infections, provided other public safety measures are adopted."https://t.co/gn8MzrYVxE pic.twitter.com/qGfQLMzDEW

— Eric Topol (@EricTopol) October 27, 2021

 

---

O que as vacinas contra COVID em crianças mais novas podem significar para a pandemia.

28 Out, 2021 | 16:14h

What COVID vaccines for young kids could mean for the pandemic – Nature

Conteúdo relacionado: FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

---

Confusão mental (brain fog) pode persistir durante meses após o diagnóstico de COVID.

28 Out, 2021 | 16:11h

Assessment of Cognitive Function in Patients After COVID-19 Infection – JAMA Network Open

Comentários:

Brain fog can persist 8 months after COVID diagnosis – CIDRAP

Brain fog in Covid-19 patients can persist for months, even in those who were not hospitalized, study finds – CNN

---

Revisão sistemática | Antibióticos profiláticos para prevenir infecções por Gram-positivos associadas a cateter venoso central de longa permanência em adultos e crianças em tratamento oncológico.

28 Out, 2021 | 16:07h

Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer – Cochrane Library

---

A procalcitonina tem utilidade clínica no tratamento da pneumonia pediátrica adquirida na comunidade? Um debate de prós e contras.

28 Out, 2021 | 16:02h

Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate – JAC-Antimicrobial Resistance

PRO: Procalcitonin has clinical utility in children with community-acquired pneumonia

CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia

---

Estudo de coorte retrospectiva | Corticoterapia está relacionada a menor necessidade de drenagem cirúrgica em pacientes pediátricos com abscessos retro e parafaríngeos.

28 Out, 2021 | 15:58h

Corticosteroids in the Treatment of Pediatric Retropharyngeal and Parapharyngeal Abscesses – Pediatrics

---

Painel consultivo do FDA recomenda que a vacina da Pfizer contra a Covid-19 seja autorizada para crianças de 5 a 11 anos de idade.

27 Out, 2021 | 12:44h

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children – STAT

Ver também:

Tracking the FDA advisory panel meeting on Covid-19 vaccines for kids – STAT

FDA advisory panel recommends Pfizer vaccine for kids ages 5 to 11 – NPR

---

Covid-19 em indivíduos já vacinados ocorre com mais frequência naqueles com baixos níveis de anticorpos.

27 Out, 2021 | 12:42h

Breakthrough Infections Occur in Those with Lower Antibody Levels, Israeli Study Shows – NIH Director’s Blog

Estudo original: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

---

Vacinação heteróloga AstraZeneca/Pfizer parece estar associada com maior efetividade contra Covid-19 em comparação com a vacinação homóloga Pfizer/Pfizer.

27 Out, 2021 | 12:41h

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination – Nature

Conteúdos relacionados:

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

Should You Mix and Match Your Booster Shot?

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

A dose of the AstraZeneca COVID-19 vaccine followed by a dose of the Pfizer/BioNTech vaccine confers better protection against SARS-CoV-2 infection than two doses of the Pfizer vaccine, according to a study in healthcare workers published in @Nature. https://t.co/6hIVkiOLQ1 pic.twitter.com/AmsyVUMpoj

— Nature Portfolio (@NaturePortfolio) October 26, 2021

 

---